Related Experiment Video
Updated: Jul 4, 2026

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
Published on: May 17, 2024
Continuous Glucose Monitoring Metrics and Perinatal Outcomes in Pregnant Women with Type 2 Diabetes
Angel Chemoul1, Soulaima Trigui1, Alina Ciofu1
1Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France.
Background:
The rising incidence of early-onset type 2 diabetes (T2D) has made it the leading cause of pregestational diabetes worldwide. However, real-world data on glycemic control during pregnancy and its association with perinatal outcomes remain limited.
Objective:
To examine associations between continuous glucose monitoring (CGM)-derived metrics and perinatal outcomes throughout pregnancy and across gestational windows in women with T2D.
Methods:
We conducted a single-center retrospective cohort study including all pregnant women with T2D who delivered between January 2020 and August 2025 and used CGM for ≥7 days (n = 80). The primary composite outcome included preterm birth (<37 weeks), large-for-gestational-age infant, neonatal hypoglycemia, shoulder dystocia, neonatal intensive care admission, hyperbilirubinemia, or perinatal mortality. CGM metrics included mean glucose, time in range (TIR63-140), time below range, and glucose coefficient of variation. Associations were assessed using mean differences and adjusted logistic regression.
Results:
Among 80 women (mean (±standard deviation) age 34 ± 6 years; body mass index 33 ± 7 kg/m2; glycated hemoglobin 7.4% ± 1.7%), 24 (30%) were diagnosed during pregnancy. Median (interquartile range) CGM use was 118 (69-187) days. Mean TIR63-140 was 72% ± 13%; 50 (63%) women achieved TIR63-140 ≥70%, 19 (24%) achieved ≥80%, and only 5 (6%) achieved the ≥90% target. Perinatal events occurred in 53 (66%) women. Mean glucose was higher (+11 mg/dL; 95% confidence interval [CI], +5 to +16) and TIR lower (-8.1 percentage points; 95% CI, -13.2 to -3.0) in women with events, with differences apparent from 9 to 12 weeks of gestation. Each 10-point decrease in TIR63-140 was associated with higher odds of perinatal events (adjusted odds ratio 1.82; 95% CI, 1.19-3.00). No significant differences were observed for other CGM-derived metrics.
Conclusion:
In women with T2D, poorer CGM-assessed glycemic control was associated with perinatal events from early pregnancy. Few women achieved the recommended glycemic targets, highlighting the need for improved management and prevention.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hyperglycemia
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
